These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8816843)
1. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer. van Dongen GA; Brakenhoff RM; ten Brink CT; van Gog FB; de Bree R; Quak JJ; Snow GB Anticancer Res; 1996; 16(4C):2409-13. PubMed ID: 8816843 [TBL] [Abstract][Full Text] [Related]
2. Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients. Colnot DR; Nieuwenhuis EJ; Kuik DJ; Leemans CR; Dijkstra J; Snow GB; van Dongen GA; Brakenhoff RH Clin Cancer Res; 2004 Dec; 10(23):7827-33. PubMed ID: 15585614 [TBL] [Abstract][Full Text] [Related]
3. Quantitative molecular detection of minimal residual head and neck cancer in lymph node aspirates. Nieuwenhuis EJ; Jaspars LH; Castelijns JA; Bakker B; Wishaupt RG; Denkers F; Leemans CR; Snow GB; Brakenhoff RH Clin Cancer Res; 2003 Feb; 9(2):755-61. PubMed ID: 12576446 [TBL] [Abstract][Full Text] [Related]
4. Sensitive detection of squamous cells in bone marrow and blood of head and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction. Brakenhoff RH; Stroomer JG; ten Brink C; de Bree R; Weima SM; Snow GB; van Dongen GA Clin Cancer Res; 1999 Apr; 5(4):725-32. PubMed ID: 10213205 [TBL] [Abstract][Full Text] [Related]
5. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours. Quak J; Gerretsen M; De Bree R; Brakenhof R; Van Dongen G; Snow G Anticancer Res; 1993; 13(6B):2533-9. PubMed ID: 8135493 [TBL] [Abstract][Full Text] [Related]
6. PET monitoring of therapy response in head and neck squamous cell carcinoma. Schöder H; Fury M; Lee N; Kraus D J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408 [TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma. Shores CG; Yin X; Funkhouser W; Yarbrough W Arch Otolaryngol Head Neck Surg; 2004 Aug; 130(8):937-42. PubMed ID: 15313863 [TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma. Cheng J; Ekberg T; Engström M; Nestor M; Jensen HJ; Tolmachev V; Anniko M Laryngoscope; 2007 Jun; 117(6):1013-8. PubMed ID: 17440426 [TBL] [Abstract][Full Text] [Related]
9. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Tan A; Adelstein DJ; Rybicki LA; Saxton JP; Esclamado RM; Wood BG; Lorenz RR; Strome M; Carroll MA Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):435-40. PubMed ID: 17515501 [TBL] [Abstract][Full Text] [Related]
10. [Current trends in diagnosis and treatment head and neck cancer]. Lacau St Guily JL Rev Prat; 2006 Oct; 56(15):1652-7. PubMed ID: 17137249 [TBL] [Abstract][Full Text] [Related]
11. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026 [TBL] [Abstract][Full Text] [Related]
12. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020 [TBL] [Abstract][Full Text] [Related]
14. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685 [TBL] [Abstract][Full Text] [Related]
15. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Becker MT; Shores CG; Yu KK; Yarbrough WG Arch Otolaryngol Head Neck Surg; 2004 Jan; 130(1):21-7. PubMed ID: 14732763 [TBL] [Abstract][Full Text] [Related]
16. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Kienstra MA; Neel HB; Strome SE; Roche P Head Neck; 2003 Jun; 25(6):457-63. PubMed ID: 12784237 [TBL] [Abstract][Full Text] [Related]
17. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Colnot DR; Ossenkoppele GJ; Roos JC; Quak JJ; de Bree R; Börjesson PK; Huijgens PC; Snow GB; van Dongen GA Clin Cancer Res; 2002 Nov; 8(11):3401-6. PubMed ID: 12429627 [TBL] [Abstract][Full Text] [Related]
18. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. de Bree R; Roos JC; Plaizier MA; Quak JJ; van Kamp GJ; den Hollander W; Snow GB; van Dongen GA Br J Cancer; 1997; 75(7):1049-60. PubMed ID: 9083342 [TBL] [Abstract][Full Text] [Related]
19. Progress in radioimmunotherapy of head and neck-cancer (review). Vandongen G; Brakenhoff R; Debree R; Gerretsen M; Quak J; Snow G Oncol Rep; 1994 Jan; 1(1):259-64. PubMed ID: 21607350 [TBL] [Abstract][Full Text] [Related]
20. Role of squamous cell carcinoma antigen 1 expression in the invasive potential of head and neck squamous cell carcinoma. Nakashima T; Yasumatsu R; Kuratomi Y; Masuda M; Kuwano T; Toh S; Umezaki T; Cataltepe S; Silverman GA; Komune S Head Neck; 2006 Jan; 28(1):24-30. PubMed ID: 16155915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]